Sandoz Begins Phase III Clinical Trial for Biosimilar Adalimumab
![](/46/pdcnewsitem/03/29/11/EPioE1MSSx6X0kw.jpg)
Sandoz, the global leader in biosimilars, announced it has initiated a Phase III clinical trial with its biosimilar version of adalimumab (AbbVie's HUMIRA) — the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease. This is Sandoz's eighth Phase III trial initiation across six compounds.
The aim of the study is to demonstrate equivalent efficacy, similarity and immunogenicity of the Sandoz product versus HUMIRA in patients with moderate to severe plaque-type psoriasis. Sandoz is working closely with physicians and patients on this global trial, which spans 12 countries across Europe, the US and Asia including Japan.
Psoriasis affects approximately 3% of the world's population[1]. There is significant unmet need in psoriasis with between nine and 30 percent of patients with severe psoriasis receiving no treatment at all[2]. "Because psoriasis is a chronic condition that often requires lifelong management, treatment can become a significant financial strain for many patients and healthcare systems," said Professor Dr Peter van de Kerkhof, Chairman of the Department of Dermatology at the Radboud University Nijmegen Medical Centre in The Netherlands and President of the International Psoriasis Council (IPC) Board of Directors. "A high-quality and clinically proven biosimilar version of adalimumab could play a meaningful role in alleviating cost burdens related to this disease."
"This latest advancement in our pipeline represents our unwavering commitment to expanding patient access to biologics, particularly in disease areas where there is a significant need for more treatment choices," said Mark McCamish, MD, PhD, and Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz. "We look forward to bringing a high-quality and affordable biosimilar version of adalimumab to individuals around the world living with psoriasis and other debilitating autoimmune diseases such as rheumatoid arthritis."
"Adalimumab will be a key building block in our growing Immunology portfolio, which includes other biosimilar candidates currently in Phase III trials such as etanercept (Amgen's Enbrel) and rituximab (Roche's Rituxan/MabThera)," said Ameet Mallik, Sandoz' Head of Biopharmaceuticals and Oncology Injectables. "This key development milestone further strengthens our global leadership in biosimilars and builds on our industry-leading pipeline."
Sandoz is the pioneer in biosimilars and the global market leader with over 50% market segment share of all biosimilars approved in the highly regulated markets of US, Canada, Europe, Japan and Australia. All three Sandoz biosimilars occupy the #1 biosimilar position (volume market share) in their respective categories. Sandoz biosimilars are sold in more than 50 countries and have generated in excess of 100 million patient exposure days in experience.
Footnotes
HUMIRA is a registered trademark of AbbVie
ENBREL is a registered trademark of Amgen
Rituxan/MabThera are registered trademarks of Roche
References
[1] www.worldpsoriasisday.com/web/page.aspx?refid=114. Accessed August 2013.
[2] A.W. Armstrong, et al., JAMA Dermatol. 14 August 2013.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance